Intestinal drug adsorption and bioavailability: Beyond involvement of single transport function

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 4, 2003, Pages 429-433

  Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ATORVASTATIN; BREAST CANCER RESISTANT PROTEIN 1; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; FEXOFENADINE; FLUINDOSTATIN; GLYCOPROTEIN P; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; PROTEIN; QUINIDINE; RIFAMPICIN; TALINOLOL; UNCLASSIFIED DRUG; VERAPAMIL; XENOBIOTIC AGENT; DRUG;

CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; NONHUMAN; NOTE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN TRANSPORT; BIOAVAILABILITY; INTESTINE; METABOLISM; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; HUMANS; INTESTINAL ABSORPTION; INTESTINES; PHARMACEUTICAL PREPARATIONS;

EID: 0038399856     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702973     Document Type: Note

References (49)

1. Angelin, B., Arvidsson, A., Dahlqvist, R., Hedman, A., Schenck-Gustafsson, K. (1987) Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest. 17: 262-265
2. Amidon, G. L., Lennernas, H., Shah, V. P., Crison, J. R. (1995) A theoretical basis of a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413-420
3. Borst, P., Elferink, R. O. (2002) Mammalian abc transporters in health and disease. Annu. Rev. Biochem. 71: 537-592
4. Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., Whitfield, L. (2000) Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40: 91-98
5. Chiou, W. L., Chung, S. M., Wu, T. C., Ma, C. (2001) A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in human. Int. J. Clin. Pharmacol. Ther. 39: 93-101
6. Cummins, C. L., Jacobsen, W., Benet, L. Z. (2002) Unmasking the dynamic interplay between intestinal p-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300: 1036-1045
7. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., Kim, R. B. (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27: 866-871
8. Davit, B., Reynolds, K., Yuan, R., Ajayi, F., Connor, D., Fadiran, E., Gillespie, B., Sahajwalla, C., Huang, S. M., Lesko, L. J. (1999) FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J. Clin. Pharmacol. 39: 899-910
9. Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M., Fromm, M. F. (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53: 526-534
10. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P., Hebert, M. F. (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther. 62: 41-49
11. Fricker, G., Miller, D. S. (2002) Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol. Toxicol. 90: 5-13
12. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., Beglinger, C. (1996) Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br. J. Pharmacol. 118: 1841-1847
13. Fromm, M. F., Busse, D., Kroemer, H. K., Eichelbaum, M. (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796-801
14. Fromm, M. F., Kauffmann, H. M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., Schrenk, D. (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157: 1575-1580
15. Gramatte, T., Oertel, R. (1999) Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66: 239-245
16. Gramatte, T., Oertel, R., Terhaag, B., Kirch, W. (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 59: 541-549
17. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., Von Richter, O., Zundler, J., Kroemer, H. K. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104: 147-153
18. Hamman, M. A., Bruce, M. A., Haehner-Daniels, B. D., Hall, S. D. (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 69: 114-121
19. Hedman, A., Angelin, B., Arvidsson, A., Dahlqvist, R., Nilsson, B. (1990) Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther. 47: 20-26
20. Hedman, A., Angelin, B., Arvidsson, A., Beck, O., Dahlqvist, R., Nilsson, B., Olsson, M., Schenck-Gustafsson, K. (1991) Digoxin-verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther. 49: 256-262
21. Hoffmeyer, S., Burk, O., Von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97: 3473-3478
22. Hunter, J., Hirst, B. H., Simmons, N. L. (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10: 743-749
23. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., Wilkinson, G. R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101: 289-294
24. Lennernäs, H. (1998) Human intestinal permeability. J. Pharm. Sci. 87: 403-410
25. Lennernäs, H., Ahrenstedt, O., Hallgren, R., Knutson, L., Ryde, M., Paalzow, L. K. (1992) Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9: 1243-1251.
26. Lindahl, A., Sandstrom, R., Ungell, A. L., Abrahamsson, B., Knutson, T. W., Knutson, L., Lennernas, H. (1996) Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60: 493-503
27. Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H. L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., Watkins, P. B. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62: 248-260
28. Petri, N., Lennernäs, H. (2003) In vivo permeability studies in the GI tract. In: van der Waterbeemd, H., Lennernäs, H., Artursson, P. (eds) Drug Bioavailability, Estimation of Solubility, Permeability, Absorption and Bioavailability. Wiley-VCH, Berlin, Germany, pp. 178-203
29. Von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., Dent, J., Somogyi, A. A., Eichelbaum, M. (2001) Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther. 70: 217-227
30. Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., Kasuga, M., Okumura, K. (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18: 1400-1404
31. Sandström, R., Karlsson, A., Knutson, L., Lennernas, H. (1998) Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15: 856-862
32. Sandström, R., Knutson, T. W., Knutson, L., Jansson, B., Lennernas, H. (1999) The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48: 180-189
33. Schwarz, U. I., Gramatte, T., Krappweis, J., Oertel, R., Kirch, W. (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 38: 161-167
34. Simpson, K., Jarvis, B. (2000) Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59: 301-321
35. Soldner, A., Christians, U., Susanto, M., Wacher, V. J., Silverman, J. A., Benet, L. Z. (1999) Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm. Res. 16: 478-485
36. Spahn-Langguth, H., Langguth, P. (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12: 361-367
37. Sun, D., Lennernas, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., Fleisher, D., Lee, K. D., Amidon, G. L. (2002) A comparison of human and Caco 2 gene expression profiles for 12,000 genes and the permeabilities of 26 drugs in the human intestine and Caco 2 cells. Pharm. Res. 19: 1400-1416
38. Suzuki, H., Sugiyama, Y. (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12: 3-12
39. Tannergren, T., Knutson, T., Knutson, L., Lennernäs, H. (2003) The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine: Experience from a regional perfusion technique. Br. J. Clin. Pharmacol. 55: 182-190
40. Van Telligen, O. (2001) The importance of drug-transporting P-glycoproteins in toxicology. Toxicol. Lett. 120: 31-41
41. Tucker, G. T., Houston, J. B., Huang, S. M. (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus. Br. J. Clin. Pharmacol. 52: 107-117.
42. Wacher, V. J., Wu, C. Y., Benet, L. Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13: 129-134
43. Wacher, V. J., Silverman, J. A., Wong, S., Tran-Tau, P., Chan, A. O., Chai, A., Yu, X. Q., O'Mahony, D. P., Ramtoola, Z. (2002) Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J. Pharmacol. Exp. Ther. 303: 308-813
44. Van Der Waterbeemd, H., Smith, D. A., Beaumont, K., Walker, D. K. (2001) Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44: 1313-1333
45. Watkins, P. B. (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Delivery Rev. 27: 161-170
46. Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernas, H., Karlen, A. (1998) Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41: 4939-4949
47. Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M. L., Lee, V. H., Hussain, A. S. (2002) Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm. Res. 19: 921-925
48. Zhang, Y., Benet, L. Z. (2001) The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40: 159-168
49. Van Zuylen, L., Verweij, J., Nooter, K., Brouwer, E., Stoter, G., Sparreboom, A. (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin. Cancer Res. 6: 2598-2603